Back

Optimal supraventricular tachycardia therapy mandates 3D mapping: discussion

14 April 2026 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: Young guns vs. experience Supraventricular Tachycardia (Non-Atrial Fibrillation) EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

5 More presentations in this session

Presentation thumbnail
Optimal supraventricular tachycardia therapy mandates 3D mapping: pro
Doctor V. Maslova (Kiel, DE)
Slides
Presentation thumbnail
Optimal supraventricular tachycardia therapy mandates 3D mapping: con
Doctor C. Lemes (Linz, AT)
Slides
Presentation thumbnail
Drug therapy or ablation for my patient with supraventricular tachycardia? Drug therapy is a viable treatment option
Doctor L. Perrotta (Florence, IT)
Slides
Presentation thumbnail
Drug therapy or ablation for my patient with supraventricular tachycardia? Beyond outmoded therapies: ablation is the standard of care
Doctor C. Teres (Lausanne, CH)
Slides
Presentation thumbnail
Drug therapy or ablation for my patient with supraventricular tachycardia? discussion

Access the full session

Session thumbnail
Young guns vs. experience

The Event

Event poster

EHRA 2026

14 April 2026 11:05 CET
You may be interested in
thumbnail
Congress Session
How to differentiate supraventricular tachycardias in the electrophysiology lab
thumbnail
Congress Session
How to differentiate wide complex tachycardias in the electrophysiology lab
thumbnail
Congress Session
When the rhythm is of the essence

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources